p53 Gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma

Journal of Clinical Oncology

Volumn 18, Issue 23, 2000, Pages 3936-3945

  Lavarino, Cinzia ^a   Pilotti, Silvana ^a   Oggionni, Maria ^a   Gatti, Laura ^a   Perego, Paola ^a   Bresciani, Gianluigi ^a   Pierotti, Marco A ^a   Scambia, Giovanni ^a   Ferrandina, Gabriella ^a   Fagotti, Anna ^a   Mangioni, Costantino ^a   Lucchini, Valeria ^a   Vecchione, F Francesca ^a   Bolis, Giorgio ^a   Scarfone, Giovanna ^a   Zunino, Franco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DNA; CISPLATIN; PACLITAXEL; PROTEIN P53;

ADULT; ADVANCED CANCER; AGED; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DNA DAMAGE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICROSATELLITE INSTABILITY; ONCOGENE; OVARY CARCINOMA; PRIORITY JOURNAL; REMISSION; SEQUENCE ANALYSIS; SINGLE STRAND CONFORMATION POLYMORPHISM;

EID: 0034551724     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.23.3936     Document Type: Article

References (31)

1. New cytostatic drugs in ovarian cancer
2. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
3. Role of apoptotic response in cellular resistance to cytotoxic agents
4. Apoptosis and chemotherapy resistance
5. Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies
6. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma
7. p53 in drug resistance in ovarian cancer
8. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis
9. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma
10. Distinct mdm2/p53 expression patterns in liposarcoma subgroups: Implications for different pathogenetic mechanisms
11. Detection of p53 mutation, loss of heterozygosity and DNA content in fine-needle aspirates of breast carcinoma
12. Loss of DNA mismatch repair in acquired resistance to cisplatin
13. Polymorphism at codon 213 within the p53 gene
14. Prognostic significance of p53 gene alterations in node-negative breast cancer
15. TP53 and MYC gene alterations independently predict poor prognosis in breast cancer patients
16. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis
17. Role of oncogenes in resistance and killing by cancer therapeutic agents
18. p53 mutation, allele loss on chromosome 17p, and DNA content in ovarian carcinoma
19. Prognostic factors in ovarian cancer
20. New therapy for ovarian cancer
21. Ovarian cancer cisplatin-resistant cell lines: Multiple changes including collateral sensitivity to Taxol
22. Molecular mechanisms of resistance to taxanes and therapeutic implications
23. BCL-2 family proteins: Regulators of cell death involved in the pathogenesis of cancer and resistance to therapy
24. Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis
25. High-dose cisplatin and cyclophosphamide with glutathione in the treatment of advanced ovarian cancer
26. Dose intensification of platinum compounds with glutathione protection as induction chemotherapy for advanced ovarian carcinoma
27. Comparison of mutations of Ki-RAS and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors
28. The role of DNA mismatch repair in platinum drug resistance
29. First-line chemotherapy for advanced ovarian cancer: Paclitaxel, cisplatin and the evidence
30. Dose-intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer